82420-35-7

Usage

Uses

Used in Pharmaceutical Research:
5-Fluoro-2-nitro benzylbromide is used as a key intermediate in the development of new drugs. Its unique structure allows for the creation of diverse chemical compounds with potential therapeutic applications. It is particularly valuable in the synthesis of pharmaceuticals targeting various diseases and conditions.
Used in Agrochemical Research:
In the agrochemical industry, 5-Fluoro-2-nitro benzylbromide is employed as a precursor for the synthesis of new pesticides. Its chemical properties enable the production of effective and environmentally friendly pest control agents, contributing to sustainable agriculture.
Used in Organic Synthesis:
5-Fluoro-2-nitro benzylbromide is utilized as a reagent in the synthesis of complex organic molecules. Its versatility in undergoing nucleophilic substitution reactions makes it a valuable component in the preparation of a wide range of chemical compounds for various applications.
Used in Chemical Production:
As a valuable chemical, 5-Fluoro-2-nitro benzylbromide is involved in the production of diverse chemical compounds with potential applications in the pharmaceutical and agricultural industries. Its unique structure and reactivity contribute to the development of innovative and effective products in these sectors.

Upstream product

• 446-33-3 5-Fluoro-2-nitrotoluene 
• 287121-32-8 (5-Fluoro-2-nitrophenyl)-methanol 
• 558-13-4 carbon tetrabromide 
• 395-81-3 5-fluoro-2-nitrobenzaldehyde 

Downstream Products

• 108857-29-0 ethyl (5-fluoro-2-nitrobenzyl)aminoacetate 
• 82420-38-0 Ethyl 2-Acetamido-2-(5'-fluoro-2'-nitrobenzyl)malonate 
• 223787-45-9 diethyl (5-fluoro-2-nitrophenyl)methylphosphonate 
• 108857-19-8 methyl N-<<2-amino-5-(2,4-dimethylimidazol-1-yl)phenyl>methyl>glycinate 
• 108857-11-0 7-(2,4-dimethylimidazol-1-yl)-1,2,3,5-tetrahydroimidazo<2,1-b>quinazolin-2(1H)-one 
• 108857-30-3 ethyl N-(trifluoroacetyl)-N-<(5-fluoro-2-nitrophenyl)methyl>glycinate 
• 108857-32-5 ethyl N-(trifluoroacetyl)-N-<<2-amino-5-(2,4-dimethylimidazol-1-yl)phenyl>methyl>glycinate 
• 121375-12-0 [(2-Nitro-5-[1,2,4]triazol-1-yl-benzyl)-(2,2,2-trifluoro-acetyl)-amino]-acetic acid ethyl ester 
• 108857-31-4 ethyl N-(trifluoroacetyl)-N-<<2-nitro-5-(2,4-dimethylimidazol-1-yl)phenyl>methyl>glycinate 
• 82420-45-9 3-Amino-3,4-dihydro-6-fluoro-1-hydroxycarbostyril Hydrochloride 
• 82420-51-7 3-Amino-8-chloro-6-fluoro-3,4-dihydro-1H-quinolin-2-one; hydrochloride 
• 82420-41-5 5-Fluoro-2-nitrophenylalanine Hydrochloride 
• 1644-82-2 2-fluoro-6-nitrobenzaldehyde 
• 888022-76-2 di-tert-butyl N-(5-fluoro-2-nitrobenzyl)imidodicarbonate 

Relevant academic research and scientific papers

Intramolecular Pd-catalyzed reductive amination of enolizable sp3-C-H bonds

A palladium-catalyzed reductive cyclization of nitroarenes has been designed to construct sp3-C-NHAr bonds from sp3-C-H bonds by using an enolizable nucleophile to intercept a nitrosoarene intermediate. Exposure of ortho-substituted nitroarenes to 5 mol ?% of Pd(OAc)2 and 10 mol ?% of phenanthroline under 2 atm of CO constructs partially saturated 5-, 6-, or 7-membered N-heterocycles using α-pyridyl carboxylates, malonates, 1,3-dimethylbarbituric acid, 1,3-diones, or difurans as the nucleophile.

HETEROCYCLIC SULFONAMIDES AS INHIBITORS OF TRANSFER RNA SYNTHETASE FOR USE AS ANTIBACTERIAL AGENTS

The present invention provides aromatic sulphonamides as tRNA synthetase inhibitors and process for their synthesis, pharmaceutical composition and method for treatment. Compounds disclosed can be used as antibacterial agents for the treatment or prevention of conditions caused by or contributed by aerobic and anaerobic Gram-positive pathogens, more particularly against bacterium, for example Staphylococcus, Enterococci and Streptococci. Compounds disclosed are used in particular for the treatment of skin and soft tissue infection, Formula (I)

Synthetic studies on indolocarbazoles: Total synthesis of staurosporine aglycon

A synthesis of staurosporine aglycon and its analogs was achieved in a 28-36% overall yield starting from 2-methylindole. The prominent key steps for the synthesis of the indolocarbazole alkaloids involved electrocyclization and nitrene insertion reactions.

Bicyclic And Tricyclic Compounds As KAT II Inhibitors

Compounds of Formula X: wherein A, X, Y, Z, R5, R6a, and R6b are as defined herein, and pharmaceutically acceptable salts thereof, are described as useful for the treatment of cognitive deficits associated with schizophrenia and other neurodegenerative and/or neurological disorders in mammals, including humans.

SUBSTITUTED 7-SULFANYLMETHYL-, 7-SULFINYLMETHYL- AND 7-SULFONYLMETHYLINDOLES AND THE USE THEREOF

The present application relates to novel 7-sulfanylmethyl-, 7-sulfinylmethyl- and 7-sulfonylmethylindole derivatives, processes for the preparation thereof, the use thereof alone or in combinations for the treatment and/or prevention of diseases, and the use thereof for the manufacture of medicaments for the treatment and/or prevention of diseases, especially for the treatment and/or prevention of cardiovascular disorders.

Structure-activity relationships of 3,4-dihydro-1H-quinazolin-2-one derivatives as potential CDK5 inhibitors

Cyclin-dependent kinase 5 (CDK5) is a serine/threonine kinase that plays a critical role in the early development of the nervous system. Deregulation of CDK5 is believed to contribute to the abnormal phosphorylation of various cellular substrates associated with neurodegenerative disorders such as Alzheimer's disease, amyotrophic lateral sclerosis, and ischemic stroke. Acyclic urea 3 was identified as a potent CDK5 inhibitor and co-crystallographic data of urea 3/CDK2 enzyme were used to design a novel series of 3,4-dihydroquinazolin-2(1H)-ones as CDK5 inhibitors. In this investigation we present our synthetic studies toward this series of compounds and discuss their biological relevance as CDK5 inhibitors.

2, 3, 4, 5-TETRAHYDRO-1H-[1, 4] BENZODIAZEPINE-3-HYDROXAMIC ACIDS AS MATRIX METALLOPROTEINASE INHIBITORS

Compounds having formula (1) are useful in treating disease conditions mediated by matrix metalloproteinases and TACE, such as tumor growth, osteoarthritis, rheumatoid arthritis and degenerative cartilage loss.

2-oxo-1,3,4-trihydroquinazolinyl derivatives and methods of use

Selected compounds are effective for treatment of diseases, such as cell proliferation or apoptosis mediated diseases. The invention encompasses novel compounds, analogs, prodrugs and pharmaceutically acceptable derivatives thereof, pharmaceutical compositions and methods for prophylaxis and treatment of diseases and other maladies or conditions involving stroke, cancer and the like. The subject invention also relates to processes for making such compounds as well as to intermediates useful in such processes.

2,3,4,5-tetrahydro-1H-(1,4)benzodiazepine-3-hydroxamic acids

Compounds having the following formula: ? are useful in treating disease conditions mediated by matrix metalloproteinases and TACE, such as tumor growth, osteoarthritis, rheumatoid arthritis and degenerative cartilage loss.

Synthesis of substituted 10,11-dihydro-5H-dibenz[b,f]azepines; key synthons in syntheses of pharmaceutically active compounds

Substituted 10,11-dihydro-5H-dibenz[b,f]azepines are key synthons in the syntheses of a number of pharmaceutically active compounds such as imipramine, chlorimipramine, and desimipramine analogues. A facile synthesis of substituted 10,11-dihydro-5H-dibenz[b,f]azepines is described, starting out from commercially available 2-bromotoluenes or 2-nitrotoluenes. Initial α-bromination with N-bromosuccinimide and subsequent reaction with triethylphosphite afforded the corresponding benzyl phosphonic ester derivatives. After reaction with benzaldehyde derivatives, the expected Horner-Emmons reaction products were obtained. Hydrogenation gave the amino derivatives which were transformed into the corresponding formamides. Under Goldberg conditions [1], the final ring closing step was performed to give the substituted 10,11-dihydro-5H-dibenz[b,f]azepines in 46-75% yield.